Anti-growth factor activities of benzothiophenes in human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 94, Issue 5, 2005, Pages 451-460

  Freiss, G ^a,c   Galtier, F ^a,c   Puech, C ^a,c   Aknin, C ^a,c   Maudelonde, T ^b,c   Chalbos, D ^a,c   Vignon, F ^a,c  

^a INSERM   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Anti IGF I; Benzothiophenes; Breast cancer

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL] BENZO[B]THIOPHENE; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; BENZODIAZEPINE DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; COMPLEMENTARY RNA; ESTRADIOL; FULVESTRANT; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; RALOX; RALOXIFENE; SOMATOMEDIN C; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN ANTAGONISTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLIDINES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 18144423478     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.12.043     Document Type: Article

References (40)

1. R. Peto, J. Boreham, M. Clarke, C. Davies, and V. Beral UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years Lancet 2000 1822
2. G. Freiss, C. Prebois, F. Vignon, and L. William McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms Breast Cancer Res. Treat. 1993 57 68
3. R.B. Dickson, and M.E. Lippman Growth factors in breast cancer Endocr. Rev. 1995 559 589
4. C.L. Smith, and B.W. O'Malley Coregulator function: a key to understanding tissue specificity of selective receptor modulators Endocr. Rev. 2004 45 71
5. F. Vignon, M.M. Bouton, and H. Rochefort Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens Biochem. Biophys. Res. Commun. 1987 1502 1508
6. E. Shaulian, and M. Karin AP-1 as a regulator of cell life and death Nat. Cell Biol. 2002 E131 E136
7. R. Wisdom, and I.M. Verma Proto-oncogene FosB: the amino terminus encodes a regulatory function required for transformation Mol. Cell Biol. 1993 2635 2643
8. A. Philips, D. Chalbos, and H. Rochefort Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis J. Biol. Chem. 1993 14103 14108
9. Y. Liu, J. Ludes-Meyers, Y. Zhang, D. Munoz-Medellin, H.T. Kim, C. Lu, G. Ge, R. Schiff, S.G. Hilsenbeck, C.K. Osborne, and P.H. Brown Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth Oncogene 2002 7680 7689
10. G. Freiss, and F. Vignon Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells Mol. Endocrinol. 1994 1389 1396
11. J. Saras, L. Claesson-Welsh, C.H. Heldin, and L.J. Gonez Cloning and characterization of PTPL1, a protein tyrosine phosphatase with similarities to cytoskeletal-associated proteins J. Biol. Chem. 1994 24082 24089
12. T. Sato, S. Irie, S. Kitada, and J.C. Reed FAP-1: a protein tyrosine phosphatase that associates with Fas Science 1995 411 415
13. G. Freiss, C. Puech, and F. Vignon Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells Mol. Endocrinol. 1998 568 579
14. G. Bompard, C. Puech, C. Prebois, F. Vignon, and G. Freiss Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells J. Biol. Chem. 2002 47861 47869
15. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, J.A. Cauley, L. Norton, T. Nickelsen, N.H. Bjarnason, M. Morrow, M.E. Lippman, D. Black, J.E. Glusman, A. Costa, and V.C. Jordan The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 1999 2189 2197
16. J.A. Cauley, L. Norton, M.E. Lippman, S. Eckert, K.A. Krueger, D.W. Purdie, J. Farrerons, A. Karasik, D. Mellstrom, K.W. Ng, J.J. Stepan, T.J. Powles, M. Morrow, A. Costa, S.L. Silfen, E.L. Walls, H. Schmitt, D.B. Muchmore, V.C. Jordan, and L.G. Ste-Marie Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res. Treat. 2001 125 134
17. B. Wasylyk, J.L. Imler, B. Chatton, C. Schatz, and C. Wasylyk Negative and positive factors determine the activity of the polyoma virus enhancer alpha domain in undifferentiated and differentiated cell types Proc. Natl. Acad. Sci. U.S.A. 1988 7952 7956
18. L. Tora, A. Mullick, D. Metzger, M. Ponglikitmongkol, I. Park, and P. Chambon The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties EMBO J. 1989 1981 1986
19. A. Philips, C. Teyssier, F. Galtier, C. Rivier-Covas, J.M. Rey, H. Rochefort, and D. Chalbos FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells Mol. Endocrinol. 1998 973 985
20. C. Teyssier, K. Belguise, F. Galtier, and D. Chalbos Characterization of the physical interaction between estrogen receptor alpha and JUN proteins J. Biol. Chem. 2001 36361 36369
21. J. Sambrook, E.F. Fritsch, and T. Maniatis Molecular Cloning: A Laboratory Manual 1989 Cold Spring Harbor Laboratory Press Cold Spring Harbor, New York, U.S.A.
22. A. Philips, C. Teyssier, F. Galtier, C. Rivier-Covas, J.M. Rey, H. Rochefort, and D. Chalbos FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells Mol. Endocrinol. 1998 973 985
23. T.A. Grese, and J.A. Dodge Selective estrogen receptor modulators (SERMs) Curr. Pharm. Des 1998 71 92
24. P.D. Delmas, H.K. Genant, G.G. Crans, J.L. Stock, M. Wong, E. Siris, and J.D. Adachi Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 2003 522 532
25. E.E. Jolly, N.H. Bjarnason, P. Neven, L. Plouffe Jr., C.C. Johnston Jr., S.D. Watts, C.D. Arnaud, T.M. Mason, G. Crans, R. Akers, and M.W. Draper Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 2003 337 344
26. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, C. Christiansen, P.D. Delmas, J.R. Zanchetta, J. Stakkestad, C.C. Gluer, K. Krueger, F.J. Cohen, S. Eckert, K.E. Ensrud, L.V. Avioli, P. Lips, and S.R. Cummings Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators JAMA 1999 637 645
27. A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, J. Adachi, G. Wells, B. Shea, and G. Guyatt Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis Endocr. Rev. 2002 524 528
28. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 1998 1371 1388
29. L.E. Rutqvist, H. Johansson, T. Signomklao, U. Johansson, T. Fornander, N. Wilking Stockholm Breast Cancer Study Group Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies J. Natl. Cancer Inst. 1995 645 651
30. T.J. Powles Anti-oestrogenic chemoprevention of breast cancer-the need to progress Eur. J. Cancer 2003 572 579
31. K. Paech, P. Webb, G.G. Kuiper, S. Nilsson, J. Gustafsson, P.J. Kushner, and T.S. Scanlan Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites Science 1997 1508 1510
32. R.V. Weatherman, N.J. Clegg, and T.S. Scanlan Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites Chem. Biol. 2001 427 436
33. P. Webb, P. Nguyen, and P.J. Kushner Differential SERM effects on corepressor binding dictate ERalpha activity in vivo J. Biol. Chem. 2003 6912 6920
34. R.V. Weatherman, and T.S. Scanlan Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites J. Biol. Chem. 2001 3827 3832
35. C. Teyssier, D. Chen, and M.R. Stallcup Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function J. Biol. Chem. 2002 46066 46072
36. R. Reiter, A.S. Oh, A. Wellstein, and A.T. Riegel Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity Oncogene 2004 403 409
37. R. Poulin, Y. Merand, D. Poirier, C. Levesque, J.M. Dufour, and F. Labrie Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells Breast Cancer Res. Treat. 1989 65 76
38. A.M. Oleksik, T. Duong, N. Pliester, G. Asma, C. Popp-Snijders, and P. Lips Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis J. Clin. Endocrinol. Metab. 2001 2763 2768
39. R. Torrisi, L. Baglietto, H. Johansson, G. Veronesi, B. Bonanni, A. Guerrieri-Gonzaga, B. Ballardini, and A. Decensi Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer Br. J. Cancer 2001 1838 1841
40. W. Jochum, E. Passegue, and E.F. Wagner AP-1 in mouse development and tumorigenesis Oncogene 2001 2401 2412